IDM Pharma Reports 2008 Financi...(000) Net loss $(1857000) $...)

Date:3/31/2009

000) Net loss $(1,857,000) $(2,682,000) $(18,606,000) $(18,350,000) Weighted average number of shares outstanding 25,451,015 25,146,206 25,265,558 21,075,738 Basic and diluted loss per share $(0.07) $(0.11) $(0.74) $(0.87) Comprehensive loss: Net loss $(1,857,000) $(2,682,000) $(18,606,000) $(18,350,000) Other comprehensive (loss) gain (99,000) 1,094,000 (617,000) 2,041,000 $(1,956,000) $(1,588,000) $(19,223,000) $(16,309,000)

                                     IDM PHARMA, INC.
                           CONDENSED CONSOLIDATED BALANCE SHEETS
                                        (unaudited)

                                              December 31,      December 31,
                                                    2008              2007

    ASSETS
    Current assets:
     Cash and cash equivalents                 $12,752,000       $28,382,000
     Other current assets                          755,000         4,786,000
    Total current assets                        13,507,000        33,168,000

    Property and equipment, net                    242,000           513,000
    Patents, trademarks and other licenses, net  2,642,000         2,734,000
    Goodwill                                     2,812,000         2,812,000
    Other long-term assets                         473,000           832,000
    Total Assets                               $19,676,000       $40,059,000

    LIABILITIES AND STOCKHOLDERS' EQUITY
     Common stock warrants                      $3,522,000          $450,000
     Other current liabilities                   5,794,000        11,712,000
     Other liabilities                           1,211,000         1,874,000
     Stockholders' equity                        9,149,000        26,023,000
    Total liabilities and
'/>"/>
SOURCE  IDM Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 
Related biology technology :

1. Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors
2. The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health
3. Recent Graduates Finding BioTech & Pharmaceutical Jobs Easier Than Ever With The Launch of CampusRXBio
4. VIA Pharmaceuticals Complies With NASDAQ Rules
5. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
6. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
8. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
9. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
10. Isis Pharmaceuticals to Present at the 4th Annual Citi Biotech Day
11. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results